D. Boral Capital Begins Coverage on Pulmonx (NASDAQ:LUNG)

D. Boral Capital initiated coverage on shares of Pulmonx (NASDAQ:LUNG) in a report issued on Monday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $17.00 price target on the stock. D. Boral Capital’s price target indicates a potential upside of 132.88% from the company’s current price.

Other analysts also recently issued research reports about the company. Wells Fargo & Company cut their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 11th. Citigroup reiterated a “neutral” rating and set a $7.50 target price (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.36.

Pulmonx Trading Up 1.1 %

NASDAQ LUNG opened at $7.30 on Monday. Pulmonx has a 1-year low of $5.46 and a 1-year high of $10.01. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a 50-day moving average of $6.98 and a 200-day moving average of $6.94. The firm has a market cap of $290.51 million, a PE ratio of -5.07 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. As a group, sell-side analysts forecast that Pulmonx will post -1.55 EPS for the current year.

Insiders Place Their Bets

In related news, insider Geoffrey Beran Rose sold 5,779 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total value of $41,204.27. Following the completion of the transaction, the insider now owns 285,278 shares of the company’s stock, valued at $2,034,032.14. The trade was a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Glendon E. French III sold 55,453 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $8.28, for a total transaction of $459,150.84. Following the completion of the transaction, the director now directly owns 1,011,974 shares of the company’s stock, valued at $8,379,144.72. This trade represents a 5.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,986 shares of company stock valued at $986,673 over the last 90 days. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC grew its holdings in shares of Pulmonx by 11.2% during the third quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after buying an additional 591,859 shares during the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Pulmonx during the fourth quarter valued at $10,421,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Pulmonx by 5.2% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after buying an additional 55,279 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Pulmonx by 2.4% during the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock valued at $8,750,000 after buying an additional 25,002 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Pulmonx by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock valued at $6,128,000 after purchasing an additional 9,454 shares during the period. 91.04% of the stock is owned by hedge funds and other institutional investors.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.